Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1
CBT for Depression & Adherence in HIV Methadone Patients
Patients with HIV, depression, and opioid-dependence are at high risk for poor health outcomes. This is a two-arm randomized controlled trial of cognitive-behavioral therapy for depression and HIV medication adherence in patients with opioid dependence who are receiving methadone maintenance treatment. The project is based on our pilot work with close attention to NIDA guidelines for a staged approach to treatment development and testing (Rounsaville et al., 2001).
Depression is highly comorbid with both HIV infection and with opioid dependence. Depression and substance abuse are both associated with poor adherence to antiretroviral medications. Patients with HIV, depression, and opioid dependence are at high risk for poor health outcomes. Cognitive-behavioral therapy is the most widely studied and efficacious psychosocial intervention for depression; and research by the PI and others has shown that cognitive-behavioral interventions have been successful in promoting adherence to HIV medications.
연구 개요
상세 설명
Symptoms of depression (i.e. low motivation, poor concentration, loss of interest, sad mood, suicidal ideation) that occur in the context of substance abuse or dependence can interfere with self-care behaviors necessary for maintaining HIV care, as well as interfere with potential benefit from an intervention that focuses on adherence alone. We hypothesize that teaching skills to cope with depression will improve the outcome from an adherence intervention to promote healthier living with HIV, in HIV+ opioid dependent individuals in methadone maintenance treatment.
Overview of Research Plan. Patients who are HIV positive and who are receiving methadone maintenance for opioid dependence will be randomized to treatment with either: (1) CBT, a combination of CBT for depression and HIV medication adherence, including a single session intervention for HIV medication adherence (Life-Steps, Safren et al., 2001) in conjunction with physician feedback regarding baseline study assessments or (2) the single session intervention for HIV medication adherence (Life-Steps, Safren et al., 2001) in conjunction with physician feedback regarding baseline study assessments. Participants will be followed for one-year post-randomization.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- HIV seropositive
- Currently enrolled in methadone maintenance treatment for at least one month
- Current major or subsyndromal depression (subsyndromal depression is defined by major depression that does not meet full diagnostic criteria but with a clinical global impression of severity (CGI-S) of 2 (mildly ill))
- Is prescribed antiretroviral therapy for HIV and therefore under the care of a primary care provider.
- Between the ages of 18 and 65.
Exclusion Criteria:
- Active untreated, unstable, major mental illness (i.e., untreated psychosis or mania), or other Axis I psychiatric disorders (other than depression) that would interfere with the ability to participate (i.e. CGI-S >6)
- Unable or unwilling to provide informed consent.
- Currently in cognitive behavioral therapy for depression.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: CBT-AD
Cognitive behavioral therapy for adherence and depression
|
Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
|
|
활성 비교기: ETAU
Enhanced treatment as usual
|
Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percent Medication Adherence at 3-month Follow-up Assessment
기간: 3-month assessment
|
Post-treatment assessment in adherence to HIV medication.
Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report.
Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.
|
3-month assessment
|
|
Percent Medication Adherence at 12-month Follow-up Assessment
기간: 12-month follow-up assessment
|
Follow-up assessment in adherence to HIV medication.
Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report.
Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.
|
12-month follow-up assessment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Clinician-assessed Depression Rating at 3 Month Follow-up Assessment
기간: 3 month follow-up
|
Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition.
The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.
|
3 month follow-up
|
|
HIV Viral Load at 12-month Follow-up Assessment
기간: 12-month follow-up assessment
|
HIV plasma RNA (log HIV viral load)at the 12-month follow-up assessment.
|
12-month follow-up assessment
|
|
CD4+ Lymphocyte Count at 12-month Follow-up Assessment.
기간: 12-month follow-up assessment
|
CD4+ lymphocyte cell count at 12-month follow-up assessment.
|
12-month follow-up assessment
|
|
Clinician-assessed Depression at 12-month Follow-up Assessment
기간: 12-month follow-up assessment
|
Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition.
The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.
|
12-month follow-up assessment
|
|
HIV Viral Load at 3-month Follow-up Assessment
기간: 3-month assessment
|
HIV plasma RNA (log HIV viral load)at the 3-month follow-up assessment.
|
3-month assessment
|
|
CD4+ Lymphocyte Count at 3-month Follow-up Assessment.
기간: 3-month assessment
|
CD4+ lymphocyte cell count at 3-month follow-up assessment.
|
3-month assessment
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Steven Safren, Ph.D., Massachusetts General Hospital
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NIDA-18603-1
- R01DA018603 (미국 NIH 보조금/계약)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
CBT-AD에 대한 임상 시험
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)완전한
-
Baylor College of MedicineNational Institute of Mental Health (NIMH)완전한
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)완전한